Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086]
Eur J Med Chem. 2020 Sep 1:201:112404.
doi: 10.1016/j.ejmech.2020.112404.
Epub 2020 Jun 8.
1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.
2 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taiwan.
3 Graduate Institute of Pharmacognosy, Taipei Medical University, Taiwan; Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan.
4 Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan.
5 Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan.
6 TMU Biomedical Commercialization Center, Taipei Medical University, Taiwan.
7 Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taiwan.
8 Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan; Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taiwan.
9 Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan; Traditional Herbal Medicine Research Center of Taipei Medical University Hospital, Taipei, 11031, Taiwan. Electronic address: mcchen1250@tmu.edu.tw.
10 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan; TMU Biomedical Commercialization Center, Taipei Medical University, Taiwan; Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taiwan. Electronic address: jpl@tmu.edu.tw.